Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Panagiotis Kokkoris

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Endocrinology and Metabolism Clinics of North America|January 9, 2004
Obesity and endocrine diseasePanagiotis Kokkoris, F Xavier Pi-Sunyer
Clinical Endocrinology|March 5, 2013
Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosisPolyzois Makras, Stergios A Polyzos, Athanasios Papatheodorou, et al.
Hormones (Athens, Greece)|April 12, 2014
The AGT and the GNB3 polymorphisms and insulin resistance in prehypertensionChristos Maniotis, Klio Chantziara, Panagiotis Kokkoris, et al.
Pediatric Blood & Cancer|May 7, 2011
Reduced bone mineral density in adult patients with Langerhans cell histiocytosisPolyzois Makras, Evangelos Terpos, George Kanakis, et al.
Metabolism: Clinical and Experimental|May 20, 2017
Low periostin levels in adult patients with Langerhans cell histiocytosis are independently associated with the disease activityAthanasios D Anastasilakis, Stergios A Polyzos, Marina Tsoli, et al.
Clinical Cases in Mineral and Bone Metabolism : the Official Journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases|December 22, 2017
Periostin and sclerostin levels in juvenile Paget's diseaseStergios A Polyzos, Polyzois Makras, Athanasios D Anastasilakis, et al.
Journal of Bone and Mineral Metabolism|June 10, 2015
Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver diseaseStergios A Polyzos, Athanasios D Anastasilakis, Jannis Kountouras, et al.
Metabolism: Clinical and Experimental|July 23, 2015
Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markersAthanasios D Anastasilakis, Stergios A Polyzos, Zoe A Efstathiadou, et al.
Archives of Osteoporosis|October 17, 2018
Serum 25-hydroxyvitamin D status, quantitative ultrasound parameters, and their determinants in Greek populationEffimia V Grigoriou, George Trovas, Nikolaos Papaioannou, et al.
Expert Opinion on Therapeutic Targets|November 15, 2014
Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatmentAthanasios D Anastasilakis, Stergios A Polyzos, Polyzois Makras, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Endocrinology and Metabolism Clinics of North America|January 9, 2004
Obesity and endocrine diseasePanagiotis Kokkoris, F Xavier Pi-Sunyer
Clinical Endocrinology|March 5, 2013
Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosisPolyzois Makras, Stergios A Polyzos, Athanasios Papatheodorou, et al.
Hormones (Athens, Greece)|April 12, 2014
The AGT and the GNB3 polymorphisms and insulin resistance in prehypertensionChristos Maniotis, Klio Chantziara, Panagiotis Kokkoris, et al.
Pediatric Blood & Cancer|May 7, 2011
Reduced bone mineral density in adult patients with Langerhans cell histiocytosisPolyzois Makras, Evangelos Terpos, George Kanakis, et al.
Metabolism: Clinical and Experimental|May 20, 2017
Low periostin levels in adult patients with Langerhans cell histiocytosis are independently associated with the disease activityAthanasios D Anastasilakis, Stergios A Polyzos, Marina Tsoli, et al.
Clinical Cases in Mineral and Bone Metabolism : the Official Journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases|December 22, 2017
Periostin and sclerostin levels in juvenile Paget's diseaseStergios A Polyzos, Polyzois Makras, Athanasios D Anastasilakis, et al.
Journal of Bone and Mineral Metabolism|June 10, 2015
Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver diseaseStergios A Polyzos, Athanasios D Anastasilakis, Jannis Kountouras, et al.
Metabolism: Clinical and Experimental|July 23, 2015
Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markersAthanasios D Anastasilakis, Stergios A Polyzos, Zoe A Efstathiadou, et al.
Archives of Osteoporosis|October 17, 2018
Serum 25-hydroxyvitamin D status, quantitative ultrasound parameters, and their determinants in Greek populationEffimia V Grigoriou, George Trovas, Nikolaos Papaioannou, et al.
Expert Opinion on Therapeutic Targets|November 15, 2014
Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatmentAthanasios D Anastasilakis, Stergios A Polyzos, Polyzois Makras, et al.
Pageof 1